Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + azacitidine
- Development stage
- Unknown
- Lead developer
- Bayside Health
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
everolimus + azacitidine is a combination therapy investigated for the treatment of acute myeloid leukemia (AML), particularly in elderly patients or those with relapsed/refractory disease. Everolimus is a small molecule inhibitor of the mechanistic target of rapamycin (mTOR), specifically targeting the mTORC1 complex to inhibit protein synthesis and cell cycle progression. Azacitidine is a hypomethylating agent and pyrimidine nucleoside analog that incorporates into DNA and RNA, leading to the inhibition of DNA methyltransferases (DNMTs). This dual approach aims to overcome resistance mechanisms in AML by simultaneously targeting epigenetic dysregulation and the PI3K/Akt/mTOR signaling pathway. Clinical development for this combination in AML has been primarily led by Bayside Health in Phase 1 trials.
- Brand names
- AfinitorVidaza
- Other names
- RAD001 + 5-azacitidineEverolimus and azacitidine
02
Targets
Mechanistic target of rapamycin complex 1DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on everolimus + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + azacitidine.